Original StudyMIDTERM RESULTS OF LOW-DOSE INTRAVITREAL TRIAMCINOLONE AS ADJUNCTIVE TREATMENT FOR PROLIFERATIVE VITREORETINOPATHYChen, Weiqi MD*; Chen, Haoyu MD*†; Hou, Ping MB*; Fok, Andrew MBChB†; Hu, Yijun MB*; Lam, Dennis S C MD, FRCS, FRCOphth*†Author Information From the *Joint Shantou International Eye Center of the Shantou University & the Chinese University of Hong Kong, Shantou, China; and †Department of Ophthalmology and Visual Sciences, The Chinese of University Hong Kong, 3/F Hong Kong Eye Hospital, Kowloon, Hong Kong, China. Supported in part by the Joint Shantou International Eye Center Intramural Grant (07-016), the National Nature Science Foundation of China (30901646), and the Science and Technology Project of Shantou City (2009-70). None of the authors have proprietary interest. Reprint requests: Dennis S. C. Lam, MD, FRCS, FRCOphth, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong, China; e-mail: [email protected] Retina: June 2011 - Volume 31 - Issue 6 - p 1137-1142 doi: 10.1097/IAE.0b013e3181fe5427 Buy Metrics AbstractIn Brief Purpose: To evaluate the midterm anatomical and functional outcomes of intravitreal injection of low-dose triamcinolone acetonide in silicone oil-filled eyes as an adjunctive treatment for proliferative vitreoretinopathy. Methods: This is a retrospective interventional case series. Patients with proliferative vitreoretinopathy grade C or D received pars plana vitrectomy combined with silicone oil tamponade and intravitreal injection of 2 mg of triamcinolone acetonide in the first stage and silicone oil removal in the second stage. Primary outcome measures were retinal reattachment rate and best-corrected visual acuity. Results: In all, 37 eyes from 37 patients were included in this study. The mean follow-up duration was 22.9 ± 9.6 months. Retina was reattached in 36 (97.3%) eyes at the last visit. The mean best-corrected visual acuity was 1.76 ± 0.56 logMAR at baseline, which improved to 0.87 ± 0.60 logMAR at the last visit (P < 0.001). Best-corrected visual acuity increased in 31 (83.8%) eyes, remained unchanged in 5 (13.5%) eyes, and decreased in 1 (2.7%) eye at last visit compared with baseline. Conclusion: Low-dose (2 mg) triamcinolone acetonide intravitreal injection as an adjunct to vitrectomy and silicone oil tamponade in treating proliferative vitreoretinopathy (grade C or D) appears to be effective and safe. Intravitreal injection of 2 mg of triamcinolone acetonide as adjunctive therapy with vitrectomy and silicone oil tamponade for proliferative vitreoretinopathy resulted in retina reattachment and visual acuity improvement in most cases without severe complication. © The Ophthalmic Communications Society, Inc.